Profil
Pamela Holland worked as the Vice President of Cancer Biology at Surface Oncology, Inc. She then served as the Senior Vice President of Research at Alpine Immune Sciences, Inc. Dr. Holland holds a doctorate degree from the University of Washington and an undergraduate degree from the University of California San Diego.
Ehemalige bekannte Positionen von Pamela Holland
| Unternehmen | Position | Ende |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2023 |
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | - |
Ausbildung von Pamela Holland
| University of California San Diego | Undergraduate Degree |
| University of Washington | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
